XNCR
Xencor Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Xencor has 11 disclosed suppliers and 9 disclosed customers in SEC filings.
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
SentenceIn February 2025, we entered into a master services agreement with Alimentiv Inc. for contract research organizations ("CROs") services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn April 2021, we entered into a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody reactive with human CLDN6, which is used in our XmAb541 program.
XNCR 10-Kaccession 0001326732-26-000015
SentenceICON Clinical Research Limited provides clinical services for our Xencor-sponsored oncology trials.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn July 2014, we entered into a master services agreement with KBI Biopharma, Inc. for process development, clinical scale-up, analytical method development, formulation development, and related drug substance and drug product services for certain antibody candidates, including XmAb541 and plamotamab.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn August 2023, we entered into a master services agreement with OncoBay Clinical, Inc., now known as Kapadi, for CROs services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).
XNCR 10-Kaccession 0001326732-26-000015
SentencePAREXEL conducts clinical studies for our plamotamab program.
XNCR 10-Kaccession 0001326732-26-000015
SentencePPD Development, L.P. conducts clinical studies for our vudalimab program.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn December 2015, we entered into a master services agreement with Selexis SA for the manufacture of proprietary cell lines.
XNCR 10-Kaccession 0001326732-26-000015
SentenceVetter Pharma International GmbH currently manufactures drug products for our XmAb819 and XmAb541 programs.
XNCR 10-Kaccession 0001326732-26-000015
SentenceWuXi currently manufactures drug substance and drug product for our XmAb808, XmAb657, XmAb942 and XmAb412 programs.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn September 2020, we entered into a license agreement (the "2020 Xencor Agreement") with Xencor, to obtain (i) an exclusive, royalty-bearing, sublicensable worldwide license under certain patent rights controlled by Xencor and (ii) a non-exclusive payment bearing license under certain know-how controlled by Xencor to research, develop, manufacture, market and sell three antibody product candidates (the "2020 Licensed Assets"), including ZB002 and ZB004.
SentenceUnder the terms of the Alexion Agreement, we granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use our Xtend technology to evaluate and advance compounds.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn September 2015, we entered into a Research and License Agreement (the "Amgen Agreement") with Amgen to develop and commercialize bispecific antibody product candidates using our proprietary XmAb® bispecific Fc technology.
XNCR 10-Kaccession 0001326732-26-000015
SentenceAstellas : ASP2138 is a bispecific Claudin 18.2 x CD3 bispecific antibody that Astellas is advancing for the treatment of patients with gastric, gastroesophageal junction or pancreatic cancers.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn February 2024, Incyte assumed all of MorphoSys AG's right, title and interest under the MorphoSys Agreement.
XNCR 10-Kaccession 0001326732-26-000015
SentenceOn December 22, 2023, we entered into a Technology License Agreement with Mabgeek.
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn June 2010, we entered into a Collaboration and License Agreement with MorphoSys AG, which was subsequently amended in 2012, 2020 and 2024 (as amended, the "MorphoSys Agreement").
XNCR 10-Kaccession 0001326732-26-000015
SentenceIn June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.
XNCR 10-Kaccession 0001326732-26-000015
Xencor Inc
30.13
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+15.89%
vs ±26.0% implied · ×0.61
shaded = implied · ▲▼ = realized
Linked news
NewsExpected move
No implied move.